Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
MJFF Publications
Donate Now
Access Resources

MJFF Publications
4331 - 4340 of 8801 Results
Title
Year
  • Year
  • 2021
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2021
  • 2025
  • Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis
    2021
    Summary Details
    RESTRICTED
    Title: Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis
    Author(s): Paolo Preziosa, Piet M. Bouman, Svenja Kiljan, Martijn D. Steenwijk, Alessandro Meani, Petra J. W. Pouwels, Maria A. Rocca, Massimo Filippi, Jeroen J.G. Geurts, Laura E. Jonkman
    Journal Name: Journal of Neurology, Neurosurgery & Psychiatry
    Publisher: BMJ
    Vol: 92
    Issue #: 7
    Start Page: 790
    End Page: 792
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1136/jnnp-2020-324391
    Citation Count: 28
  • Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion
    2022
    Summary Details
    RESTRICTED
    Title: Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion
    Author(s): Patrick Oeckl, Sarah Anderl‐Straub, Christine A. F. Von Arnim, Inês Baldeiras, Janine Diehl‐Schmid, Timo Grimmer, Steffen Halbgebauer, Anna M. de Kort, Marisa Lima, Tainá M. Marques, Marion Ortner, Isabel Santana, Petra Steinacker, Marcel M. Verbeek, Alexander E. Volk, Albert C. Ludolph, Markus Otto
    Journal Name: Journal of Neurology, Neurosurgery & Psychiatry
    Publisher: BMJ
    Vol: 93
    Issue #: 6
    Start Page: 659
    End Page: 667
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1136/jnnp-2021-328547
    Citation Count: 78
  • Serum peroxiredoxin 3 is reduced in genetic carriers of Parkinson’s disease
    2022
    Summary Details
    RESTRICTED
    Title: Serum peroxiredoxin 3 is reduced in genetic carriers of Parkinson’s disease
    Author(s): Adeline SL Ng, Jayne Tan, Ebonne Ng, Kay Yaw Tay, Wing Lok Au, Louis Tan, Eng King Tan
    Journal Name: Journal of Neurology, Neurosurgery & Psychiatry
    Publisher: BMJ
    Vol: 94
    Issue #: 3
    Start Page: 250
    End Page: 251
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1136/jnnp-2022-329433
    Citation Count: 3
  • Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease
    2022
    Summary Details
    RESTRICTED
    Title: Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease
    Author(s): Danna Jennings, Sarah Huntwork‐Rodriguez, Anastasia G. Henry, Jennifer C. Sasaki, René Meisner, Dolores Diaz, Hilda Solanoy, Xiang Wang, Elvira Negrou, Vitaliy V. Bondar, Rajarshi Ghosh, Michael T. Maloney, Nicholas E. Propson, Yuda Zhu, Romeo Maciuca, Laura Harris, Angela Kay, Peter A. LeWitt, T. Alex King, Drew S. Kern, Aaron Ellenbogen, Ira Goodman, Andrew Siderowf, Jason Aldred, Omid Omidvar, Shababa T. Masoud, Sonnet S. Davis, Annie Arguello, Anthony A. Estrada, Javier de Vicente, Zachary K. Sweeney, Giuseppe Astarita, Marie T. Borin, Bradley K. Wong, Harvey Wong, Hoang N. Nguyen, Kimberly Scearce‐Levie, Carole Ho, Matthew D. Troyer
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Vol: 14
    Issue #: 648
    Start Page:
    End Page:
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.abj2658
    Citation Count: 192
  • Monitoring gait at home with radio waves in Parkinson’s disease: A marker of severity, progression, and medication response
    2022
    Summary Details
    RESTRICTED
    Title: Monitoring gait at home with radio waves in Parkinson’s disease: A marker of severity, progression, and medication response
    Author(s): Yingcheng Liu, Guo Zhang, Christopher G. Tarolli, Rumen Hristov, Stella Jensen-Roberts, Emma Waddell, Taylor Myers, Meghan Pawlik, Julia Soto, Renée Wilson, Yuzhe Yang, Timothy Nordahl, Karlo J. Lizárraga, Jamie Adams, Ruth B. Schneider, Karl Kieburtz, Terry D. Ellis, E. Ray Dorsey, Dina Katabi
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Vol: 14
    Issue #: 663
    Start Page:
    End Page:
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.adc9669
    Citation Count: 57
  • Toward preventing Parkinson’s disease
    2022
    Summary Details
    RESTRICTED
    Title: Toward preventing Parkinson’s disease
    Author(s): Brit Mollenhauer, Christine A. F. Von Arnim
    Journal Name: Science
    Publisher: American Association for the Advancement of Science (AAAS)
    Vol: 377
    Issue #: 6608
    Start Page: 818
    End Page: 819
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1126/science.add7162
    Best OA location URL: https://resolver.sub.uni-goettingen.de/purl?gro-2/113804
    Citation Count: 15
  • Unveiling the B cell receptor structure
    2022
    Summary Details
    OPEN
    Title: Unveiling the B cell receptor structure
    Author(s): Pavel Tolar, Susan K. Pierce
    Journal Name: Science
    Publisher: American Association for the Advancement of Science (AAAS)
    Vol: 377
    Issue #: 6608
    Start Page: 819
    End Page: 820
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/science.add8065
    Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/11044948
    Citation Count: 10
  • An Overview of the Active Clinical Trials for Parkinson’s Disease Psychosis
    2022
    Summary Details
    RESTRICTED
    Title: An Overview of the Active Clinical Trials for Parkinson’s Disease Psychosis
    Author(s): Cynthia Kwan, Philippe Huot
    Journal Name: Neurodegenerative Disease Management
    Publisher: Informa UK Limited
    Vol: 12
    Issue #: 4
    Start Page: 165
    End Page: 170
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.2217/nmt-2022-0020
    Citation Count: 0
  • Optimization of Lipophilic Metalloporphyrins Modifies Disease Outcomes in a Rat Model of Parkinsonism
    2021
    Summary Details
    OPEN
    Title: Optimization of Lipophilic Metalloporphyrins Modifies Disease Outcomes in a Rat Model of Parkinsonism
    Author(s): Liping Liang, Ruth Fulton, Erica L. Bradshaw‐Pierce, Jennifer N. Pearson-Smith, Brian J. Day, Manisha Patel
    Journal Name: The Journal of Pharmacology and Experimental Therapeutics
    Publisher: Elsevier BV
    Vol: 377
    Issue #: 1
    Start Page: 1
    End Page: 10
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1124/jpet.120.000229
    Best OA location URL: https://jpet.aspetjournals.org/content/jpet/377/1/1.full.pdf
    Citation Count: 5
  • Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer Cells
    2025
    Summary Details
    RESTRICTED
    Title: Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer Cells
    Author(s): Qinheng Zheng, Tao Shen, Julius Pampel, Kevan M. Shokat
    Journal Name: ACS Chemical Biology
    Publisher: American Chemical Society (ACS)
    Vol: 20
    Issue #: 7
    Start Page: 1696
    End Page: 1706
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by,cc-by-nc-nd, cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1021/acschembio.5c00249
    Best OA location URL: https://doi.org/10.1021/acschembio.5c00249
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.